On November 3, 2026 Diakonos Oncology Corp. ("Diakonos"), a clinical-stage biotechnology company developing a new generation of immunotherapies for aggressive cancers, reported that an abstract on the clinical experience with DOC1021 (a first-in-class, patient-derived, double-loaded dendritic cell therapy) has been selected for a rapid oral presentation and poster presentation at the 31st Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO) being held in Philadelphia, November 12-15, 2026. This abstract includes data from the Phase 1 study and Expanded Access Protocol of DOC1021 in newly diagnosed and recurrent glioblastoma, and introduces the ongoing Phase 2 study in newly diagnosed glioblastoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SNO POSTER AND RAPID ORAL PRESENTATION DETAILS:
Meeting: 31st Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO); Philadelphia, PA; November 12-15, 2026
Abstract Title: Experience of DOC1021 dendritic cell vaccine (dubodencel) in newly diagnosed and recurrent glioblastoma
Abstract Code: CTIM-30
Rapid Oral Session Date and Time: Saturday, November 14, 2026, from 11:30 a.m.-12:30 p.m. ET
Poster Session Date and Time: Friday, November 13, 2026, from 7:30-9:30 p.m. ET
Presenter: Joseph Georges, DO, PhD; Arizona State University
The abstract accepted for presentation can be viewed online at the SNO conference website here.
About DOC1021
DOC1021 (dubodencel) is Diakonos’ investigational, patient-derived, double-loaded dendritic cell therapy. The product combines a patient’s dendritic cells with tumor lysate and amplified tumor-derived mRNA prepared from the patient’s tumor specimen. DOC1021 is being evaluated in clinical studies involving glioblastoma, pancreatic cancer and refractory melanoma. DOC1021 has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. The FDA has granted Fast Track Designation to DOC1021 for the treatment of pancreatic cancer, glioblastoma, and unresectable or metastatic cutaneous melanoma, and Diakonos has also received Orphan Drug Designation for the glioblastoma program.
(Press release, Diakonos Oncology, NOV 3, 2026, View Source [SID1234674129])